Abvc Biopharma ABVC Estimates

NASDAQ ABVC
$0.98 +0.01 (+0.64%)
At close: Sep 10, 2026 · 4:00 PM EDT
Analyst Estimates

Abvc Biopharma, Inc. Revenue Estimates

Periods 24
Next Period Q1 23
Consensus 0.00

Analysts expect Abvc Biopharma, Inc. to report revenue of 0.00 for Q1 23, against a range of 0.00 to 0.00. The most recent reported quarter, Q3 23, came in at 15,880.00, a 95.0% miss against the 318,474.00 consensus.

Metric Q1 22Q2 22Q3 22Q4 22Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27
Reported (Actual) 25,660.00312,860.0042,270.00589,780.00--15,880.00------
High Estimate -26,926.5928,001.3027,874.040.00347,166.35345,778.050.003.18 M3.86 M4.38 M4.37 M986,226.72
Low Estimate -22,561.1723,110.1823,409.780.00291,149.65291,169.950.002.67 M3.62 M3.66 M3.90 M872,659.90
Consensus Estimate -24,743.8825,555.7425,641.910.00319,158.00318,474.000.002.93 M3.74 M4.02 M4.13 M929,443.31
Analyst Estimates

Abvc Biopharma, Inc. Earnings Per Share (EPS) Estimates

Periods 24
Next Period Q1 23
Consensus -0.48

Analysts expect Abvc Biopharma, Inc. to report earnings per share of -0.48 for Q1 23, against a range of -0.50 to -0.46. The most recent reported quarter, Q3 23, came in at -0.82, a 121.6% miss against the -0.37 consensus.

Metric Q1 22Q2 22Q3 22Q4 22Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27
Reported (Actual) -2.05-0.60-1.10-1.50---0.82------
High Estimate --1.09-2.00-1.41-0.46-0.56-0.34-0.47-0.61-0.88-1.34-1.34-0.53
Low Estimate --1.25-2.28-1.65-0.50-0.66-0.40-0.51-0.69-1.06-1.52-1.44-0.65
Consensus Estimate --1.17-2.14-1.53-0.48-0.61-0.37-0.49-0.65-0.97-1.43-1.39-0.59